Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients;Evaluación de las reacciones adversas de los antituberculosos en pacientes hospitalizados

Pharmacy Practice

Volumn 4, Issue 3, 2006, Pages 134-138

  Gholami, Kheirollah ^a   Kamali, Elahe ^b   Hajiabdolbaghi, Mahboubeh ^a   Shalviri, Gloria ^b  

^a Instituto de Estilo de Vida   (Iran)

^b Ministerio de Sanidad   (Iran)

Author keywords

Adverse drug reaction reporting systems; Drug toxicity; Inpatients; Iran; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE SEVERITY; DYSURIA; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; IRAN; LUNG TUBERCULOSIS; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; PATIENT MONITORING; PERIPHERAL NEUROPATHY; QUESTIONNAIRE; SIDE EFFECT; SKIN DISEASE; TEACHING HOSPITAL; URIC ACID BLOOD LEVEL; URINARY TRACT DISEASE; VISUAL IMPAIRMENT;

EID: 33846087935     PISSN: 1885642X     EISSN: 18863655     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. World Health Organization. Global Tuberculosis Control. WHO report 2001. Geneva, Switzerland: WHO/CDS/TB; 2001. 27.
2. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978:117:991-1001.
3. Burman WJ. Reves RR. Hepatotoxicity from Rifampin plus Pyrazinamide. Lessons for Policymakers and Messages for Care Providers. Am J Respir Crit Care Med 2001; 164:1112-3.
4. British Thoracic and Tuberculosis Association: Short course chemotherapy in pulmonary tuberculosis. Lancet 1975; 119-24.
5. Tanaja DP, Kaur D. Study on hepatotoxicity and other side effects of antituberculosis drugs. J Indian Med Assoc 1990; 88:278-80.
6. Snider DE, Long MW, Cross FS, Farer LS. Six months Isoniazid and Rifampin therapy for pulmonary tuberculosis: report of a United States Public Health Service cooperative trial. Am Rev Respir Dis 1984; 77:233-42.
7. Sharma SK., Balamurgan A., Saha PK., Pandey RM. Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during Antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916-9.
8. World Health Organization. Uppsala Monitoring Center. Safety monitoring of medicinal products, guidelines for setting up and running pharmacovigilance center, Geneva, 1996.
9. Naranjo CA., Busto U., Sellers EM. A method for estimating the probability of Adverse Drug Reactions. Clin Pharmacother 1981; 30:239-45.
10. Hartwig SC., Siegel J., Schneider PJ. Preventability and severity assessment in reporting Adverse Drug Reactions. Am J Hosp Pharm, 1992; 49:2229-32.
11. Schumock GT, Thornton JP. Focusing on the preventability of Adverse Drug Reactions. Hosp Pharm. 1992; 27:538.
12. Yee D, Valiquette C, Pelletier M, Parislen I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Resp Crit Care Med. 2003. 167: 1472-7.
13. Gholami K., Shalviri G. Factors associated with preventability, predictability and severity of ADRs. Ann Pharmacother 1999; 33:236-40.
14. Gholami K, Parsa S, Shalviri G, Sharifzadeh M, Assasi N. Anti-infectives-induced adverse drug reactions in hospitalized patients. Pharmacoepidemiol Drug Safe 2005; 14:501-6.
15. Kays MB. Tuberculosis. In: Koda-Kimble MA, Young LY, Kradijan WA, Guglielmo JB, Allfredge BK, Corelli RL. Applied Therapeutics, The Clinical Use of Drugs. Eighth Edition 2005. Lippincott Williams and Wilkins. p.71-83.